Abatacept is under clinical development by Phaim Pharma and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abatacept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abatacept (CTLA4-Ig) is under development for the treatment of type 1 diabetes mellitus (T1DM) and pre-diabetes. The drug candidate is a fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). It is administered through intravenous route and acts by targeting CD80 and CD86.
It is also under development as a combination with an antigen based vaccine for T1DM.
Phaim Pharma overview
Phaim Pharma (Phaim) focuses on developing curative treatments for auto-immune diseases. Phaim is headquartered in London, Greater London, the UK.
For a complete picture of Abatacept’s drug-specific PTSR and LoA scores, buy the report here.